LON:STX - Shield Therapeutics Share Price, Forecast & News

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

3 analysts have issued 12 month price targets for Shield Therapeutics' shares. Their forecasts range from GBX 200 to GBX 200. On average, they anticipate Shield Therapeutics' stock price to reach GBX 200 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price. View Analyst Price Targets for Shield Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.

News articles about STX stock have been trending very negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shield Therapeutics earned a news impact score of -4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Shield Therapeutics.

Some companies that are related to Shield Therapeutics include ORGANIGRAM-TS (OGI), Hexo (HEXO), HEXO (HEXO), Next Science (NXS), ICC Labs (ICC), Benchmark (BMK), Amryt Pharma (AMYT), Probiotec (PBP), ESSA Pharma (EPI), Green Organic Dutchman (TGOD), CannTrust (TRST), Auscann Group (AC8), Flowr (FLWR), Supreme Cannabis (FIRE) and WeedMD (WMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX).

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of STX stock can currently be purchased for approximately GBX 133.

Shield Therapeutics has a market capitalization of £155.86 million and generates £14.00 million in revenue each year. Shield Therapeutics employs 15 workers across the globe.View Additional Information About Shield Therapeutics.

The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/.

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.